Q1 Earnings Estimate for Clene Issued By HC Wainwright

Clene Inc. (NASDAQ:CLNN) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Clene in a report released on Thursday, March 12th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.45) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.45) EPS.

Clene (NASDAQ:CLNN) last announced its earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.03 million.

A number of other equities analysts have also weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a research report on Thursday. Canaccord Genuity Group restated a “buy” rating and set a $48.00 price objective on shares of Clene in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. UBS Group reaffirmed a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.60.

Clene Price Performance

Clene stock opened at $5.72 on Monday. The business has a 50 day simple moving average of $4.98 and a 200-day simple moving average of $6.72. Clene has a 12 month low of $2.28 and a 12 month high of $13.50. The stock has a market capitalization of $62.06 million, a PE ratio of -2.20 and a beta of 0.62.

Insiders Place Their Bets

In other Clene news, major shareholder Chidozie Ugwumba sold 32,705 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $5.50, for a total transaction of $179,877.50. Following the sale, the insider directly owned 708,587 shares in the company, valued at approximately $3,897,228.50. The trade was a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David J. Matlin bought 33,333 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were bought at an average price of $6.50 per share, for a total transaction of $216,664.50. Following the completion of the transaction, the director directly owned 477,824 shares in the company, valued at approximately $3,105,856. This represents a 7.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 283,174 shares of company stock worth $1,518,665 in the last ninety days. 35.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Clene

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new stake in Clene during the third quarter worth about $29,000. Jane Street Group LLC purchased a new position in Clene in the second quarter valued at about $47,000. State Street Corp increased its holdings in Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after buying an additional 17,300 shares in the last quarter. PEAK6 LLC acquired a new stake in shares of Clene during the 4th quarter valued at approximately $294,000. Finally, Lunt Capital Management Inc. lifted its position in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after acquiring an additional 1,250 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).